Language selection

Search

Patent 1076565 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1076565
(21) Application Number: 1076565
(54) English Title: PROCESSES FOR THE PREPARATION OF 3',4'-DIDEOXYKANAMYCIN B
(54) French Title: PREPARATION DE LA 3',4'-DIDESOXYKANAMYCINE B
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07H 15/22 (2006.01)
(72) Inventors :
  • UMEZAWA, HAMAO
  • UMEZAWA, SUMIO
  • SEKI, SHIGEO
  • FUKATSU, SHUNZO
  • YASUDA, SHUNTARO
(73) Owners :
  • ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI
(71) Applicants :
  • ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI
(74) Agent:
(74) Associate agent:
(45) Issued: 1980-04-29
(22) Filed Date:
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


TITLE OF INVENTION:
New Processes for the Preparation of 3',4'-
Dideoxykanamycin B
ABSTRACT OF THE DISCLOSURE:
New routes are provided for the synthesis of
3',4'-dideoxykanamycin B which is effective in inhibiting
kanamycin-resistant organisms from kanamycin B through
new intermediate, of which a fundamental process comprises
a new reaction of a 3',4'-epoxy derivative of amino- and
hydroxyl-protected kanamycin B with a xanthate to form
a corresponding 3',4'-dideoxy-3'-eno derivative followed
by removal of the amino and hydroxyl-protecting groups
thereof and by hydrogenation of the resulting 3',4'-
dideoxy-3'-eno-kanamycin B. A 3',4'-episulfide deriv-
ative corresponding to the 3',4'-epoxy derivative which
is formed as second product in the reaction of 3',4'-
epoxy derivative with xanthate is also used as intermediate
for the preparation of 3',4'-dideoxykanamycin B.
- 1 -


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiments of the invention in which an exclusive
property or privilege is claimed are defined as follows:
1. A process for the preparation of an intermediate
used in the production of 3',4'-dideoxy-kanamycin B or its acid
addition salts which comprises treating with a xanthate a 3',4'-
epoxy derivative of an amino- and hydroxyl-protected kanamycin B
of the formula:
<IMG>
(I)
<IMG>
wherein R represents a hydrogen atom or an alkyl or
aryl group, Z represents an alkylidene, arylidene, cyclo-
hexylidene or tetrahydropyranylidene group and the 3',
4'-epoxy group is in .alpha.- or .beta.-position whereby to form
a 3',4'-dideoxy-3'-eno-kanamycin B derivative of the
formula:
42

<IMG>
(II)
<IMG>
wherein R and Z have the same meaning as defined above
and isolating the 3',4'-dideoxy-3'-eno-kanamycin B derivative
from the reaction mixture.
2. A process as claimed in Claim 1 wherein the xanthate
is an alkali metal xanthate.
3. A process as claimed in Claim 1 wherein the
treatment with a xanthate is carried out in an organic solvent.
4. A process as claimed in Claim 3 wherein the solvent
is a lower alkanol.
5. A process as claimed in Claim 1 wherein the
treatment with a xanthate is carried out at a temperature of
50°- 100°C.
6. A process as claimed in Claim 1 wherein the
isolation of 3',4'-dideoxy-3'-eno-kanamycin B derivative is
effected by a chromatographic separation.
7. A compound of the formula
43

<IMG>
(II)
<IMG>
wherein R represents a hydrogen atom or an alkyl or aryl group
and Z represents an alkylidene, arylidene, cyclohexylidene or
tetrahydropyranylidene group, whenever produced by the process
of Claim 1 or an obvious chemical equivalent thereof.
44

Description

Note: Descriptions are shown in the official language in which they were submitted.


6S~5
BACKGROUND OF THE INVENTION:
. .. ~
This invention relates to new routes for the
synthesis of 3',4'-dideoxykanamycin B which is anti-
bacterial against a variety of gram~positive and gram-
negative bacteria and particularly effective in inhibit~ng
kanamycin-resistant organisms such as kanamycin-resistant -
Staphylococci and kanamycin-resistant Escherichia coli.
DESCRIPTION OF THE PRIOR ART:
3'94'-Dideoxykanamycin B having the structure:
~,
~ .
:~/ . 6"
~ HOC~2 j
L~'~O~
~~
OH
'~ ~ 10
has hitherto been prepared by a method comprising pro-
tecting the five amino groups and all or a part of the
. hydroxyl groups other than 3'- and 4'-hydroxyl groups
of kanamycin B by a conventional method, sulIonylating
the 3'- and 4'-hydroxyl groups to afford a derivative
having 3'- and 4'-disulfonic ester groups, removing the
3'- and 4'-disulfonic ester groups by known methods to
give a 3',4'-unsaturated compound, reducing the 3',4'-
'
:

~L~76~
- unsaturated compound and removing the residual protecting
groups. The known method requires nine steps from kana-
mycin B to 3',4'-dideoxykanamycin B (see British Patent
Specification No. 1,349,302). Furtherg the method re-
quires the use of sodium iodide and zinc powder in large
amounts in the step for removing the 3'- and 4'-disulfonic
ester groups, thus involving questions of iodine resources
and of environmental pollution resulting from disposal
of by-products. Therefore, the development of new, more
;~ 10 advantageous method for synthesis of 3',4'-dideoxykanamycin
B has eagerly been desired from the industrial point of
view.
SUMMARY OF THE INVENTION:
It is the primary object of this invention to pro-
vide some new routes for the synthetic preparation of 3',
4'-dideoxykanamycin B which are advantageous over the
prior art in that they do not use an alkali metal bromide
or iodide and zinc powder, but use other reagents of less
expenses. All the new processes originate from kanamycin
B as in the prior art but pass through a new route of
reaction.
According to a first aspect of this invention,
therefore, there is provided a process for the preparation
of 3',4'-dideoxykanamycin B or its acid addition salts and
inte~iates thereof o~rismg one or mDre of the folla~ng steps:
(1) treating with a xanthate a 3','l'-epoxy derivative of
an amino- and hydroxyl-protected kanamycin B of the formula:
~.

~7~i~65
CH2NHCOOR NHCOOR
HCOOR
~0~ ~
~COOR
OCH2! (I)
z/~/~
OH
wherein R represents a hydrogen atom or an alkyl or aryl
group, Z represents an alkylidene, arylidene, cyclohexyli-
:dene or tetrahydropyranylidene group and the 3',4'-epoxy
: group is in a- or ~-position whereby to form a 3',4'-
dldeoxy-3'-eno-kanamycln B derivative of the formula:
C~2~COORI NHCOOR .~
~~ Y
NHCOOR ~ /
~( II )
OCH2 O
Z/~IICOO~
~o ,~4
~ . OH
: - 4

56;5
wherein R and Z have the same meaning as defined above
together with a 3',4'-episulfido-kanamycin B derivative
of the formula:
.:
CE2~HCOOR ~XCOOR
O~ ~ HCOOR
l~j--0~
NECOOR
; OCHz
(III)
OH
`'. ~ " '
. . .
wherein R and Z have the same meaning as de~ined above
: and the 3',4'-episulfide group is in ~- or ~-position;
(2) lsolatLng the 3',4'-dideoxy-3~-eno-kanamycin B
. derivative ~rom the reaction mixture;
,
(3) removing the amino-protecting groups -COOR and
hydroxyl-protecting group Z of the 3:',4t-dideoxy-3'-eno
.~ derivative thus isolated in a conventional manner to ~ :
: form 3',4'-dideoxy-3'-eno-kanamycin B of the formula: .
.
,, .
'
.':'~ ..
., .
:
:~ .
. ~ .
';'

~ ~7~
CH2 NH2 N~ ~
~io~
~H2
/
XOCH2
~ 0 ( IV )
1(~
HO \~/
OH
:
and (4) hydrogenating the compound thus formed in a
conventional manner to form 3',41-dideoxykanamycin B;
and, if desired, converting the compound~thus formed
into an acid addition salt thereof.
The step (l) of the first aspect process of this
invention~ that is the treatment of a 3~',4'-epoxy deriv-
ative o~ the formul~a (I) in either ~- or ~-form with a
xanthate, may be effected in an organic solvent, pref-
erably~at a temperature of 50_100C. The~organic
solvent may preferably be a lower alkanol such as methanol
and ethanol. ~he xanthate to be used for thls treatment
may be those of the formula R'OCSSMe where R' is a lower
alkyl group, Me is an alkali metal such as-sodium or
potassium. Generally, this reaction gives a 3',4'-
dideoxy-3'-eno derivative of the formula (II) as a first
product in admixture with a 3',4'-episulfide derivative
of the formula (III) as a second product after washing
-- 6

S~:;5
the reaction mixture wlth water, recovering the solvent
by distillation and concentrating the residue to dryness.
The mechanism of reaction between the 3',4' epoxy
derivative of the formula (I) and the xanthate has not
yet been made clear, but a presumable possibility is that
the conversion of 3',4'-epoxy derivative into correspond-
ing 3',4'-dideoxy-3'-eno derivative of the formula (II)
proceeds via corresponding 3',4'-episulfide derivative
of the formula (III).
The isolation of the ~irst and second products of
the step (1) from each other, i.e. the step (2) of the~ -
first aspect process, may be effected, preferably by
chromatography~ for~example silica-gel thin layer chromato-
graphy in a usual manner, for example using a mixture
(e.g. 1:1 by volume) o~ carbon tetrachloride and acetone
as developer.
The step (3)~of the first aspect process of this
; lnvention for the removal of the amino-protecting groups
-COOR and hydroxyl-protecting group Z may be carried out
ln a usual manne~. For example, the remo~al of the
hydroxyl-protecting group Z may ~irst be effected by a :
mild hydrolysis with a dilute hydrochloric acid or an
aqueous acetic acid and then the amino-protecting groups
may be removed by a hydrolysis with barium hydroxide or
by hydrogenolysis in the presence of a palladium catalyst.
The step (4) of the first aspect process, that is the
: hydrogenation step, may be carried out in a known manner.
Thus, a catalytic reduction with hydrogen in the presence
of a known hydrogenation catalyst comprising a platinum
group metal such as platinum or palladium may preferably
-- 7
; ,~.
.
,. . .

765~i~
be applicable to the step (4). Raney nickel catalyst
may also be used for this purpose.
The first aspect process of this invention is
advantageous over the prior art process above mentioned
in that
- the formation of 3',4'-unsaturatlon can be
achieved without relylng on the reaction involving
the use of an alkali bromide or iodide and zinc
powder;
- as the final intermediate compound which is to
be converted to the desired product, 3',4'-
dideoxykanamycin B, in the last step, 3',4'-
dideoxy 3'-eno-kanamycin B, i.e. the compound
; of the formula (IV) free from any protecting
group can be obtained;
- in the last step, the catalytic hydrogenation
can be achieved relatively easily with much less
impurities derived from reagents used, so that
~ the purification of the final product is required
;~ 20 only to a less extent than in the prior art
process wherein the step for removing amino- and
hydro~yl-protec~ing groups is carried~out after
the step for the hydrogenation.
It will be appreciated, however, that the order of
the steps (3) and (4) of the first aspect process of this
invention can be reversed, if desired, to follow the known
order adopted by the prior art process.
The final product, 3',4' dideoxykanamycin B in free
base form, may be converted, if desired, to an acid addition
salt derived from an inorganic or organic acid. For example,
; '
:. . , ' . .

~ 65~ :
sulfate of 3',4'-dideoxykanamycin B may be obtained by
adding dilute sulfuric acid to an aqueous solution of the
free base to adjust the pH value to 6.8, treating the
solution with decoloring carbon~ filkering the solution
and freeze-drying the filtrate.
We have further found that the 3',4'-episulfide
derivative of the formula (III) which is formed as second
product in the step (1) of the first aspect process of
this invention is also useful as intermediate for the
preparation of 3',~ dideoxykanamycin B. Our discovery
in this respect is that there are two routes for converting
the 3',4'-episulfide derivative of the formula (III) to
a known useful intermediate for the preparation of 3',
4'-dideoxykanamycin B; the first route is to treat the
3',4'-episulfide derivative with an acid to form 3',4'-
dideoxy-3'-eno-kanamycin B of the formula (IV) and the
second route is to treat the 3',4'-episulfide derivative
with hydrazine or Raney nickel to form a 3',4'-dideoxy-
3'-eno-kanamycin B derivative of the formula (II).
According to a second aspect process of this
invention, therefore, we provide a process for the prepara-
tion of 3',4'-dideoxykanamycin B or its acid addition saltsand
int~iates ~hereof ox~rising one or more of the follcwlng steps;
(1) treating with a xanthate a 3',4'-epoxy derivative of
an amino- and hydroxyl-protected kanamycin B of the formula:
', : ' ` , ` ` ,: '

7~5~
~H2NHCOOR ~ NHCOOR
r ~ ~NHCOOR
' fo~o
~HCOOR
OCH2 (I)
OH
wherein R represents a hydrogen atom or an alkyl or aryl
group, Z repres~nts an alkylidene, arylidene, cyclohexylidene
: - or tetrahydropyranylidene~ group and the 3',4'-epoxy group
i~ in a- or ~-position whereby to form~a 3'j4'-episulfido-
; kanamycin B derivative of the formula:
CH2NHCOOR ¦
~HCOOR
/ ~ ~HCOOR
,, ~ ' ' S~ ~0 ~
.; NHCOOR
~ ~ OC o (III)
Z~
.
.
.: '

~7G5i~
wherein R and Z have the same meaning as defined above
and the 3',4'-episulride group is in ~- or ~-position
together with a 3',4'-dideoxy-3'-eno-kanamycin B derivative '
of the f'ormula:
. .
CH2~HCOOR ¦ NXCOOR
k /1~ NHCOOR
~ O ~
NHCOOR /
: / OC~ o (II~
\o~:~
OH
wherein ~ and Z have the same meaning as defined above;
(2) isolating the 3',4'-episulfido-kanamycin B derivative
.. ~rom the reaction mixture;
(3) treating the 3',4'-eplsulfide deriva:tive thus isolated
with~an acid to form 3'~4'-dideoxy-3' eno-kanamycin B of
the rormu1a:
, : '
- 11 -
.:
., .

~7~5~5
CH2NH2 N~I2
J(~
HOCH2 o ( IV )
~0 /
¦~ N}~2 k/
HO ~
:
and (4) hydrogenating the compound thus formed in a
conventional manner to form 3',4'-dideoxykanamycin B,
and~ if deslred, converting~the compound thus formed lnto
an acid addition salt thereof.
The steps (1),(2) and (4) of the second aspect
process of this invention correspond to the steps (1),
~(2) and (4) of the first aspect process as above-mentioned,
respectively.
. .
The step ( 3 ) of the second aspect process, i.e. the
treatment o~ the 3',4'-episul~ide derivative of the formula
(III) with an acid may preferably~be carried out in a lower
alkanol such as methanol and ethanol using a hydrohalogenic
acid such as concentrated hydrochloric acid and hydrobromic
acid. In general, however, a non-oxidizing mineral acid,
for example sulfuric acid, may be used for this treatment.
Preferably, the treatment may be carried out at a tempera-
ture of 0 30C.
. ,
- 1 2 -
, . , ~ ,: : : .'
:

~7~S~5
According to a third aspect process of this inven-
tion, there is provided a process for the preparation of
3',4'-dideoxykanamycin B or lts acid addition salts and
~ in~e~meZiates thereof ccmprising one or more of the follcwing steps:
; (1) treating with a xanthate a 3',4'-epoxy derivative of
' an amino- and hydroxyl-protected kanamycin B of the formula:
" '
`:~
; ~2NHCOOR ¦ NHCOOR
RCOOR
NHCOOR
OCH2 (I)
,. /~' /
:~' ' OH.
~,:
.;. ~ . ~ , .
. wherein R represents a hydrogen atom or~an alkyl or aryl
.~ ~ group and Z represents an alkylidene3~arylidene, cyclo-
,..
: 10 hexylidene or tetrahydropyranylidene group whereby to form
a 3',4'-episulfido-kanamycin B derivatlve o~ the'~ormula:
' ' :
.
^.
`. '
.
- 13
.

76~ 5
CH2~XCOOR NHCOOR
r ~ ~ NHCOOR
~ ~ ~
NHCOOR
~ OCH~ O (III)
z/~ \1/
\o~V
OH
wherein R and Z have the same meaning as defined above
and 3',4'-episulfide group is in a- or ~-position together
with a 3',4'-dideoxy-3'-eno-kanamycin B derivative:of the
formula:
CH2~HCOORj NHCOOR
NHCOOR
~ o ~ ~
NHCOOR
(II)
OC~12 0 : ''
z~
- 14
' ' '

^-`` 76~1t;5
wherein R and Z have the same meaning as defined above;
(2) treating the reaction mixture from the step (1) with
hydrazine or Raney nickel to convert the 3',4'-episulfide
derivative of the formula (III) into a further amount of
the 3',4'-dideoxy-3'-eno-kanamycin B derivative of the
formula (II) above;
-~ (3) removing the amino-protecting groups -COOR and hydroxyl-
protecting group ~ of the 3',4'-dideoxy-3'-eno derivative
thus formed in a conventional manner to form 3',4'-dideoxy-
3'-eno-kanamycin B of the formula:
: - .
.,
CH2NH2 NH2
~'~0 ~NH2
o, J~
NH2 / ( IV )
f 2 o
ID ~b
. OH
and (4) hydrogenating the compound thus formed ln a con-
ventional manner to form 3',4'-dideoxykanamycin B-; and,
. if desired, converting the compound thus formed into an
acid addition salt thereof.
The steps (1),(3) and (4) of the third aspect process
of this invention correspond to the steps (1),(3) and (4)
of the first aspect process as above-mentioned, respectively.
- 15 - . .

,56~
In the step (2) of the third aspect process, the
treatment with hydrazine may preferably be effected in
a lower alkanol such as methanol and ethanol using hydrazine,
particularly in the form of hydrate NH2NH2-H20, at room
temperatures, usually 15~-25C. The amount of hydrazine
to be used may.preferably be about 10~30 moles per mole of
the compound of the formula (III). The treatment with
Raney nickel, if adopted for the step (2), may preferably
be carried out by dissolving the compound of the formula
(III) in a lower alkanol, for example methanol, adding
Raney nickel to the solution in an appropriate amount, for~
example threefold amount in respect of the amount of the
compound of the formula (III) on the weight basis and
maintaining the mixture under stirring at room temperatures,
usually lS 25C for 1-3 hours
.. . .
In the third aspect process of this invention, the :~
step (2) is also applicable, if desired, to.the 3',4'-
episulfide de~ivative of the formula (III) which has been ::
.
. .
; isolated from the 3'j4t-dideoxy-3'-eno derivative of the :~
20formula (II), but it is usually~advantageous to apply the
~step (2) directly to the reaction mixture from the step (l)
. .
containing both the compounds of the formulae (II) and (III3
;~ particularly in large scale operations.
: We have further found that the 3',4'-dideoxy-3'~
eno derivatives of the formula (IV) can be produced from .. .:
the 3',4'-epoxy derivatives of the formula (I) through
another route involving four steps with a high overall
yield. This route comprises the steps of
~ (l) treating a 3',4'-epoxy derivative of the formula:
: - 16

CH2NHCOOR NHCOOR
HCOOR
o ~1
; ~HCOOR
(I)
~OCH2
Z~/
~ ~ OH ~
.'' .
wherein R and Z have the same meaning:as defined above
with an acylating agent, for example benzoyl chloride, in
a conventional manner to acylate the 2"-hydroxyl group,
giving a compound of the formula: -
,. ,
:
CX2~ECOOR
HCOOR
O
NHCOOR
(V )
OCH2 O
Z~
Y
.
- 17

~7~
wherein R and Z have the same meaning as defined above and
Y represents an acyl group;
(2) treating the compound o~ the formula (V) thus obtained
with an alkali or alkaline earth metal iodide, for example
sodium iodide, preferably in the presence of sodium acetate
and glacial acetic acid, to give a compound of the formula:
CH2NHCOOR ¦ NHCOOR
COOR
NaCOOR
OCH2 O (VI)
Z\/
.~. oY , ...
. ' ~ ' " :' .
where R, Z and Y have the same meaning as defined abo~e;
(3) subjecting the compound of the formula (VI) thus
obtained to 3'-O-sulfonylation with a sulfonylating agent
such as mesyl chloride, tosyl chloride and benzylsulfonyl
chloride in a known manner, preferably in pyridine at a
temperature below 10C, to form the compound of the formula:
.'
. - 18
.,
' ' ' ' ,: '

9~ 5~i5
CH2 NHCOOR
NHCOOR
~ _o ,~
I ~ ~ O ~ o~
~HCOOR
OCH2 o (VII)
Z/~\V/
:: OY .,
:'
where R, Z and Y have the same meaning as defined above
, .
and W represents mesyl, tosyl or benzylsulfonyl group;
(4) heating the reaction mixture ~rom:the step (3) above~
preferably to a temperature of 80~100C ~o convert the .
compound of the formula (VII) into the compound of the
formula: .
~ .
C :NHCOOR ¦ NHCOOR~
NHCOOR
NHCOOR
" / - '
. OCH 2
/~ (VIII )
` OY
1 9

3L5D~6~6~i
wherein R, Z and Y have the same meaning as defined above;
and (5) treating the compound of the formula (VIII) thus
obtained with an alkali or alkaline earth metal alcoholate,
for example sodium methoxide, in a known manner to give
3',4'-dideoxy-3'-eno derivative of the formula (II) above~ :
The compound, penta-amino-protected, 4",6"-hydroxyl-
protected, 3',4'-~-epoxy derivative of kanamycin B re-
presented by the formula:
CH2NHCOOR ¦ NHCOOR
~ NHCOOR
_ O ~ OH
~ ~ ,.': -
NHCOOR / -
/ (IX)
OCH2 0 '
OH
wherein R and Z have the same meaning as~defined above ~-
which is to be used as starting compound of the first to
third aspect processes according to this invention is a
new compound and constitutes another aspect of this
invention.
The new 3',41-~-epoxy derivative of kanamycin B :
of the formula (IX) can be derived from kanamycin B through
several reaction steps as explained below.
; First of all, kanamycin B is sub~ected to amino-
- 20
.
.. ~ . .

7~5~
protecti.ng step in a known manner. Thus, kanamycin B is
-~ reacted with a chloroformate of the formula RCOOCl wherein
R represents a hydrogen atom or an alkyl or aryl group
such as phenyl to protect all the five amino groups of
; kanamycin B in the form of urethane group -NHCOOR in the
same manner as that described in Japanese Patent Publica-
tion No.7595/75, affording penta-N-protected kanamycin B
of the formula: :
''~ '
,
CX2~HCOOR~
NHCOOR
: k \i ~ HCOOR
.: xo~l ~
NHCOOR
(X)
~o~/
,:
whereln R has the same meaning as defined above.
The next step is 4",6"-hydroxyl-protecting step
which is also carried out in a known manner. Thus, the
~ compound of the formula (X) may be reacted with a known
.: hydroxyl-protecting agent selected from an alkylidenating
agent, an arylidenating agent, a cyclohexylidenating agent
and a tetrahydropyranylidenating agent. Typical examples .
of such hydroxyl-protecting agent include acetaldehyde,
2',2'-dimethoxypropane, anisaldehyde, benzaldehyde, dimethyl-
- 21

i565
acetal, tolualdehyde, l,l-dimethoxycyclohexane and l,l-
dimethoxytetrahydropyran. The reaction may preferably be
carried out in a polar organic solvent, e.g. dimethyl-
formamide in the presence of a catalytic amount of p-
toluene sulfonic acid at room temperatures, for example -
15~25C for 15-20 hours. This brings the selective in-
troduction of the hydroxyl-protecting group in 4",6"-
positions, thus yielding 4't,6"-O-protected derivative of
the formula: -
. ...
CH2~HCOOR
NHCOOR
XCOOR
Hol\~/~ O--\
NHCOOR
( XI )
~; OCH 2 O
Z~
"" '
wherein R has the same meaning as defined above and Z
represents an alkylidene, aryl~idene, cyclohexylidene or
tetrahydropyranylidene group. In this selective reaction,
it is desired that the temperature should be kept not to
exceed 30C because there may also occur the attac~ of the
hydroxyl-protecting agent on the 3'- and 4'-hydroxyl groups -
at higher temperatures.
~he compound of the formula (XI) is then subjected
- 22
. ' ' . : ~ : ~ : ., .:

to acylation reaction for the purpose of selective protec-
tion of the 2"- and 3'-hydroxyl groups with hydroxyl-
protecting group of an acyl type. The acylation step may
usually be carried out by dissolving the compound of the
formula (XI) in pyridine~ adding an acylating agent such
as an acyl chloride under a low temperature conditionj
preferably below 5C and maintaining the mixture under
stirring for several hours.
Preferred acylating agent may be an acid chloride
of an alkanoic acid having 2-4 carbon atoms such as acetyl
chloride or an aroyl chloride such as benzoyl chloride.
The use of benzoyl chloride ~s most preferred. The us~e
of a temperature below 5C for the acylation step does~
not affect the-4'- and 5-hydroxyl groups which are relative-
ly low in reactivity. Thus, 2",3'-diacyl derivative of the
formula:
., .
'
NHCOOR
!COOR
NXCOOR /:
. / (X~I)
OCH2 0
Z\/~
\~
" Y
wherein R and Z have the same meaning as defined above,
- 23

~L~7if~5~iS;
and X and Y each represent an acyl group, for example
an alkanoyl, particularly a lower alkanoyl such as acetyl
or an aroyl such as benzoyl may be produced.
In the acylation step, 21'-monoacylated derivative,
i.e. a compound of the formula (XII), but wherein X re-
presents a hydrogen atom may be obtained, if desired for
some purposes, by conducting the acylation reaction under
a milder conditions. Thus, in case of benzoyl chloride
being used as acylating agent~ a major proportion of 2"-
monobenzoyl derivative may be obtained under such condi-
tions that benzoyl chloride is added at a temperature
below 0C slowly and in small parts. On the other hand,
at least a ma~or proportion of 2",3'-dibenzoyl derivative~
may be obtained when benzoyl chloride is added at a time
at a temperature between 0C and room temperatures, pre~-
erably 0C and 5C. If 2"-monoacyl and 2",3'-diacyl
derlvatives are obtained in the form of a mixture, the
isolation of the respective derivatives may be effected
by a chromatographic separation technique in a known
manner, per se, for example by silica-gel thin-layer
- - .
chromatography using 2:1 by volume of chloroform-methanol~ ~
. . . .
- as developer.
The compound of the formula (XII) 1s then subjected
to 4'-O-sulfonylation to form 4'-O-sulfonylated derivative
of the formula:
- 24
: '
. ' . , : :" , . . ' ''' . :
, : : ' '~ . ,'.: ' . '

~7~
CH2NHCOOP~, ~IHCOOR
~ ~IICOOF(
~XCOOR
( XIII )
Z~/~/O
'' OY
wherein R, Z, X and Y have the same meaning as defined
above and W represents mesyl, tosyl or benzylsulfonyl
group. This step may preferably be carried out by re-
acting the compound of the formula (XII) with mesyl chlo-
ride, tosyl chloride br benzylsulfonyl chloride in pyridine.
~ The 4'-0-sulfonylation may be conducted ak a temperature
-~ of up to 50C. The most preferred sulfonylating agent is
mesyl chloride.
The 4'-0-sulfonylated derivative of the formula
:
(XIII) thus obtained is then converted to 3',4'-~-epoxy
derivative of the formula (IX) above-mentioned as main
product by treating it with a metal alcoholate. The
epoxidation reaction may preferably be carried out by
dissolving the compound of the formula (XIII) in a solvent,
for example water, a lower alkanol such as methanol or
ethanol, diglyme, sulforane, tetrahydrofuran or dimethyl-
sulfoxide, adding to the solution a metal alcoholate,
- 25

~ 765~i5
usually an alkali or alkaline earth metal alcoholate such
as sodium, potassium, or lithium alcoholate~ particularly
a lower alkoxide, for example sodium methoxide or sodium
ethoxide and maintaining the mixture at room temperatures,
usually 15-25C, suitably for 1-3 hours. During the
epoxidation reaction, the hydroxyl-protecting group Y in
the 2"-position is removed because of alkaline condition,
thus the free 2"-OH group is regenerated in the 3',4'~
epoxidized derivative o~ the formula (IX).
3',4'-~-Epoxy derivative corresponding to the 3',
4'-~-epoxy derivative of the formula (IX) may be deri~ed
from 3'-O-tosyl derivative corresponding to the 4'-O-
sulfonylated derivative of the formula (XIII) above, i.e.
the compound of the formula (XIII), but wherein W is
hydrogen and X is tosyl group in the same manner as that
of the 3',4'-epoxidation step as above-mentioned, i.e. ~ -
by treating with an alkali-metal alcoholate such as sodium
methoxide, details of which is given in DT-OS No.2,555,479.
A diagramatic reaction scheme is given below to
- .
? show the preparation of 3-,LI '-did~eoxykanamycin B starting
from kanamycin B via a new intermediate, 3',4'-~-epoxy
derivative of the formula (IX), which is treated according
to the processes of this invention.
:
. ~
: " "
,. .
:
- 26 -

6~
Kanamy c in B
¦ Protection of five NH2 groups
: CH2NHCOOR NXCOOR
~ ~HCOOR
HO ~ \
NHCOOR
O
HO ~ / ~- ~
.
Protection of 4"- and ~"-
OH groups with group Z
. C~2~HCOOR ¦ ~HCOOR
O ~ ~ COOR
H ~
~ICOOR
OH
: - 27

~7~5~5
Protection of 2"- and 3'-
OH groups with acyl groups
Y and X, respectively
CH2NHCOOR ~HCOOR
~ ~ ~ NHCOOR
HO ~ o
OCH2 ¦
~HCOOR ~ L__ /
Z < ~ , :~
: Oy , ' :
4'-O-Sulfonylation
(Introduction of W group)
CH2~HCOOR ~HCOOR
` k ~ ~NHCOOR
,~ WO~--' ~
'\ ~NHCOOR ~ ~ -
~ ` ' ' . '
¦ 3',4'-Epoxidation with
an alcoholate . ~-
~CH2~KCOOR NHCOOR ...
~r o~ ~ ~ ~NHCOOR~ ~ ~
I; NHCOOR / :
,,
z/~
- 28

~7~5~5
¦ Treatment with a xanthate
(Route A)(Route B)(Route C)
r ~ _ ~
C ~ HCOOR ~ COOR C,H2~HCOOR ~XCOOR
~ NHCOOR r ~ ~ COOR
~ ~ O ~ OH ~ O ~ OH
`~' H' S~/ ~
~HCOOR / ~COOR
'~ / ' /
Z/ ~ ~ ~/ Z/~/
, ` Treatment with
hydrazine or Raney nickel
(Route C)
:' ~ , .
Treatment
Hydrogenation Removal of the NH2-and OH-protections with an acid
(Route D) (Route A)(Route C) l (Route B)
~: CH2NHCOOR ~HCOOR C,H2~H2 ~H2
HCOOR ~ ~2
: NHCOOR 7 M~2 7
o o
OC~2 / HOCH2
Z\~ ~/
0~1
:; - 29

~L~7~5~S
\ Removal of the
\ NH2- and OH-protections /Hydrogenation
\(Route D) ¦ (RouteA)(Route B)(Route C)
.j . . .
CH2NH2 ~H2 ~ .
, l!~H2
.: /
., . O
; HOCH2
:~ k
~NH2
HO ~
OH
. :
Route A =~The first aspect process of this invention
Route B = The second aspect process of this invention
Route C = The~:third aspect process of this invention
Route D = An alternative of the first or third aspect
: : process of this invention ~ :
' . ' ' '
: .
.~ . - .
.
.
; - 30
'- .
' ' ' '.
. ~ . . .

7656Si
PREFERRED EMBODIMENTS OF THE INVENTION:
This invention is further illustrated by way of
Examples which include overall steps starting from
kanamycin B and leadin~ to the final product, 3',4'-
dideoxykanamycin B, through several routes according
to this invention.
Example l
(l) Preparation of penta N-ethoxycarbonylkanamycin B
Penta-N-ethoxycarbonylkanamycin B was prepared
from kanamycin B free base by the method described.in
Example l of British Patent No.l~349 ? 302.
(2) Preparation of 2",3'-di-0-benzoyl-penta-N~
ethoxycarbonyl-4",6"-0-cyclohexylidene-kanamycin B
Penta-N~ethoxycarbonylkanamycin B (lO g) was
suspended in dimethylformamide (70~1 ), to which
was added p-toluene sulfonic acid until the pH of
the suspension was~lowered below 3.0 and then added
cyclohexanedimethylketal (lO ml). The mixture was
maintained at 25C under stirring for 18 hours.~ The
completion of the reaction was confirmed~by thin layer
chromatography using silica gel (made by Merck) as
stationary phase and chloroform-methanol (lO:l by
volume3 as developer and the resulting reaction mix-
ture was neutralized with triethylamine. The neu-
tralized liquid was concentrated under vacuum to
obtain a residual liquid of 25 ml which was then dis-
solved in pyridine (150 ml). After cooling the
solution to a temperature of 0-5C, benzoyl chloride
(3.9 ml) was added thereto and the mixture was kept to
cause reaction for 3 hours. The completion of reaction
- 31
' .. , . . , ' ,. ',. . ~ , ' . : ', ~
. ~ . , . . ~ .

~C17~5
was confirmed by thin layer chromatography. Water
t5 ml~ was added to the resulting mixture and the
mixture was stirred at room temperature for 30
minutes, concentrated and poured into water (200 ml)
to form precipitate which was recovered by filtration.
Yield 12.7 g (95%). After the purification by a
- conventional silica-gel chromatography, the titled
compound had the following physical properties:
[a]D ~ 76.6 (c=l, pyridine); mp. 233~235C.
Elementary analysis:
Found: C 55.98; H 6.44; N 5.60%
Calculated for Cs 3 H73Ns 2 2
C 56.22; H 6.51; N 6.19%
(3) Preparation o~ 2",3'-di-O-benzoyl-penta-N-
ethoxycarbonyl-4",6"-O-cyclohexylidene-4'-0-mesyl-
kanamycin B
2",3'-dl-O-benzoyl-penta-N-ethoxycarbonyl-4",
6"-O-cyclohexylidene-kanamycin B (5g) was dissolved
in pyridine (100 ml), to which was added mesyl chloride
(1.4 ml) and the mixture was maintained at 4GC under
stirring for 1.5 hours. After the mixture was cooled
to room temperaturej water ~5 ml) was added to t~he
mixture to decompose the excess mesyl chloride and
the mixture was concentrated. To the concentrate was
added water (200 ml) to precipitate the titled compound,
which was recovered by filtration. Yield 5.0g (94%);
[a] D~ 103.6 ~c=l.0, pyridine); mp. 176-179C.
Elementary analysis:
Found: C 53.28; H 6.25; N 5.41; S 2.95%
Calculated for Cs4H7sNsO24S:
, ' .
- 32
,. . .
.~- . . . - . . . . . .
.. .. : , .
' ' ' ' . : .'
.

3~'7~65tiS
C 53.59; H 6.25; N 5.79; S 2.65%
(4) Preparation of 3~,4 t -~-epoxy-penta-N-ethoxy-
carbonyl-4",6"-O-cyclohexylidene-kanamycin B
2",31-Di-O-benzoyl-penta-N-ethoxycarbonyl-
4",6"-O-cyclohexylidene-4'-mesyl-kanamycin B (5 g)
was dissolved in methanol (100 ml), to which was
added sodium methylate (2.2 g). The mixture was
maintained at room temperature under stirring for
2 hours. After the completion of reaction was con-
firmed by thin layer chromatography using silica gel
as st~ationary phase and carbon tetrachloride-aceton;e
(1:1 by volume) as developer, the reaction mixture
.:
was ice cooled, neutralized with concentrated hydro-
chloric acid (1.25 ml) and concentrated. To the
neutralized concentrate was added water (100 ml) to
precipitate the titled compound which was-recovered by
filtration. Yield 3-5 g (95~); [~3D + 37.8 (c=l.0~
pyrldine), mp. 254~258C (decomposition with foaming).
Elementary analysis:
Found; C 51.86; H 6.89; N 7.58; 0 33.67%
Calculated for G3sH63NsOls:
- C 51.69; H 7.02; N 7.73, O 33.55%
(5) Preparation of 3',4'-dideoxy-3'-eno-penta-N-
ethoxycarbonyl~4"j6"-0-cyclohexylidene-kanamycin B
.
- 3',4'-~-Epoxy-penta-N-ethoxycarbonyl-4",~ f~-O-
cyclohexylidene-kanamycin B (800 mg) was suspended
in n-butanol (40 ml), to which was then added potassium
n-butylxanthate (1.7 g) and the reaction was conducted
at 80C for 4 hours. After the completion of reaction
was confirmed by silica-gel thin layer chromatography
,~ .
- 33
~. :
.
., . :
~: ' . ~ ' . ' ': '.

~al765~
using carbon tetrachloride-acetone (1:1 by volume)
as developer, the mixture was cooled and washed with
water t40 ml x 2) and the resulting butanol layer
was concentrated to dryness. Yield 900 mg. This was
confirmed by silica-gel thin layer chromatography to
be a mixture of 3',4'-dideoxy-3'-eno-penta-N-etho2y-
carbonyl-4",6"-cyclohexylidene-kanamycin B and 3',4'-
episulfido-penta-N~ethoxycarbonyl-4",6"-0-cyclohexyli-
dene-kanamycin B in approximately 1:1 proportion.
The mixture was sub;ected to silica-gel thin
layer chromatography using carbon tetrachloride-acetone
(5:1 by volume3 as developer, affording 3',4'-dideoxy-
3'-eno-penta-N-ethoxycarbonyl-4",6"-cyclohexylidene-
kanamycin B with ~]D6 of + 24.7 (c=l~.0? methanol) and
3',4'-episulfido-penta-N-ethoxycarbonyi-4",6"-0-cyclo-
hexylidene-kanamycin B with [~]D of f 10.8 (o=l.0,
H20) and melting point of 250~260C (with decomposi-
tion)~ separately.
Elementary analysis o~ the latter compound:
Found: C 50.41; H 6.95; N 7.45; S 3.48%
Calculated for C3sH63NsOisS
C~ 50.79; H 6.90; N 7.60j S 3.48%
(6) Preparatlon of 3'j4'-dideoxy-3'-eno-kanamycin B
3',4'-Dideoxy-3'-eno-penta~N-ethoxycarbonyl-
4",6"-O~cyclohexylidene-kanamycin B (475 mg) was
- . .
dissolved in methanol (5 ml), to which was added an
amount of 1 N HCl sufficient to adjust the pH value
- of the solution to 2Ø The solution was heated at
50C for 30 minutes and, after adding water (5 ml)
and then barium hydroxide octahydrate (1.4 g), further
_ 34

3L~7~5
heated to distill off the methanol and the remaining
mixture was refluxed for 8 hours and then cooléd.
Carbon dioxide gas was passed through the
cooled mixture and barium carbonate thus formed was
removed by ~iltration. Purification through a column
of Amberlite CG-50 (NH4+ form) gave the titled com-
pound. Yield 560 mg (2~%).
Elementary analysis:
Found: C 47.85; H 7.95; N 15.40%
Calculated for Cl3H3sNsOa:
C 48.11; H 7.80; N 15.59%
(7) Preparation of 3',4'-dideoxykanamycin B
3'4'-Dideoxy-3'-eno-kanam~cin B (120 mg) was
. ,
dissolved in water (4 ml), to which Raney nickel (0.2
ml) was added. Hydrogen was passed through the solution
for 2 hours under atmospheric conditions of temperat~re
and pressure. After the catalyst used was filtered off,
the filtrate was concentrated to dryness. Yield 108 mg
(95%)-
Example 2
(1) Preparation~of penta-N-t-butoxycarbonyl-kanamycin B
Kanamycin ~ (10 g) was added to a mixture o~ ~-
water (34 ml), triethylamine (24 ml3 and dimethyl-
~ormamide (48 ml). Then, t-butyl-S~(4,6-dimethyl-
pyrimidin-2-yl)-thiol-carbonate (40 g) was added to the
mixture at room temperature and the mixture was stirred
at that temperature for 18 hours. Addition of water
' (150 ml) to the mixture formed crystals which were re-
; covered by filtration and washed thoroughly with an
aqueous saturated solution of ethyl acetate. Yield 20
:.
' ~ , , :

~L~37~5~5~
g (100%3. mp.229_234~C (decomposition with foaming).
Elementary analysis:
Found: C 52.61; H 7.86, N 6.93%
Calculated for C43H77NsO20:
C 52.47; H 7.90; N 7.12%
(2) Preparation of 3',4'-~-epoxy penta-N-t-butoxy-
carbonyl-4",6"-0-cyclohexylidene-kanamycin B
~ Penta-N-t~butoxykanamycin B (10 g) was treated
; in the same ways as those described in Example 1 (2),
(3) and (4) above, yielding the titled compound. Yield
80%, [a~2D + 27(c=l.O; pyridine). mp. 232_234C
(decomposition with foaming).
(3) Preparation of 3',4'-episulfido-penta-N-t-butoxy-
carbonyl-4",6"-0-cyclohexylidene-kanamycin B
3~4~ Epoxy-penta-N-t-butoxy~Gnyl-4~6~-ok
hexylidene-kanamycin B (10 g) was suspended in n-butanol
'100 ml), to which was added potassium n-butylxanthate
(9.5 g) and the reaction was conducted at 90C for 2
hours. A~ter the reaction was completed, the mixture
was cooled and washed twice with 100 ml portions of:
water and the butanol layer separated was concentrated
to dryness, affording a mixture comprising 3'g4'-~
episulfido penta-N-t-butoxycarbonyl-4",6"-cyclohexylidene-
kanamycln:B and 3',4'-dideoxy-3'-eno-penta~N-t-butoxy-
carbonyl-4"6"-cyclohexylidene kanamycin B. Yield 11 g.
The crude product was sub~ected to silica gel chromato-
graphy using chloroform-methanol (50:1 by volume) as
developer, to isolate 3',4'-episulfido-penta-N-t-butoxy-
carbonyl-4",6"-cyclohexylidene-kanamycin B. Yield 3.g g
~5
(35%). [a]D ~ 23 (c= 1.0, pyridine). mp. 235~238C
36

~L~7~5~
(decomposition with foaming).
Elementary analysis:
Found: C 55.10; H 7.94; N 6.31; S 3.30%
Calculated for C49H~3NsO18S:
C 55.39; H 7.89; N 6.59; S 3.02%
(4) Preparation of 3',4'-dideoxy-3'-eno-kanamycin B
3',4'-EpisuLfido-penta-N-t-butoxycarbonyl-4",
- - 6"-0-cyclohexylidene-kanamycin B (1.15 g) was dissolved
in methanol (12 ml), to which was added concentrated
hydrochloric acid (3 ml) and the reaction was conducted
at room temperature for 3 hours.
The reaction mixture was concentrated to dryness
and the resulting residue was dissolved in water (18
ml) and the pH of the solution was adjusted to 6.~5 by
the addition o~ lN sodium hydroxide solution (2.5 ml).
The solution was passed through a column of 20 ml of
Amberlite CG-50 (NH4+ form). The adsorbed column was
washed with water and then O.lN aqueous ammonia and
subsequently eluated with 0.3N aqueous ammonia. The
concentration o~ the eluate gave the titled compound.
Y~eld 194 mg. ~ ~
(5) Preparation of 3',4'-dideoxykanamycin B ;
` 3'4'-Dideoxy 3'-eno-kanamycin B tl20 mg) was
.. . .
dissolved in water (4 ml), to which was added Raney
nickel (0.2 ml) and hydrogen was passed through the
mixture for 2 hours under atmospheric temperature and
pressure conditions. After the catalyst was filtered~
off, the filtrate was concentrated to dryness, giving
the tilted compound. Yield 108 mg (90%).
Example 3
- * Trade ~ark
' ~

~ 6~;i6~
Preparation of 3',4'-episulf`ido-penta-N-ethoxycarbonyl- .
4",6"-O-cyclohexylidene-kanamycin B
3',4'-a-Epoxy-penta-N-ethoxycarbonyl-4",6"-O-
cyclohexylidene-kanamycin B (100 mg) which was prepared .
;~ by the method described in Example 1 of DT-OS 2,555,479
was dissolved in pyridine (5 ml), to which was added
potassium ethyl xanthate (100 mg) and the mixture was
refluxed for 1.5 hours and then concentrated to dryness.
A mixture of water and chloroform (2:3 by volume) was
added to the solid residue and the chloro~orm layer
was separated~ washed three times with 20 ml portlons
`~ ~ OL water and concentrated to dryness, yielding 70 mg
of a crude product comprising 3'~4'-episulfido-penta-
- N-ethoxycarbonyl-4",6"-O-cyclohexylidene-kanamycirl B
and 3l,4'-dideoxy-3'-eno-penta-N-ethoxycarbonyl-4",6"-
O~cyclohexylidene-kanamycin B.
The isolation of the respective compounds was
carried out by thin layer chromatography in the same
manner as that used in Example 1 (5) above.
Example 4
: (lj Preparation of 3',4'-dideoxy-3'-eno-penta-N-
ethoxycarbonyl-4",6"-O-cyclohexylidene-kanamycin B
3',4'-Episulfido-penta-N-ethoxycarbonyl-4",6"-O-
cyclohexylidene-kanamycin B (470 m~) which was prepared
as described in Example 1 (5)(or Example 3(1)) above
was dissolved in methanol (2 ml), to which was added -
hydrazine hydrate (0.22 ml) and the mixture was allowed
to stand at room temperature for 2 hours. The reaction
mixture was then concentrated to dryness and treated
with water ~20 ml) to form precipitate which was re-
3~ -
. :
.
.

ii56~
covered by ~iltration. Yield 362 mg (80%). [~]D
24.7 (c=1.0, methanol).
Elementary analysis:
Found: C 52.31; H 7.53; N 7.49%
Calculated for C3sH6 sNsOl 8:
C 52.50; H 7.36; N 7.85%
(2) Preparation of 3',4'-dideoxy-3'-eno-kanamycin B
3',4'-Dideoxy-3'-eno-penta-N-Ethoxycarbonyl-4",
6"-cyclohexylidene-kanamycin B (475 mg) was dissolved
in methanol (5 ml) and treated in the same manner as
that described in Example 1 (6), affording the titled
compound.
(3) Preparation of 3',4'-dideoxykanamycin B
3',4'-Dideoxy-3'-eno-kanamycin B was treated
as similar as in Example 1 (7), affording the titled
compound. ~ -
Example 5
(1) Preparation o~ 3',4'-dideoxy-3'-eno-penta-N-t-
butoxy-4",6"-C-cyclohexylidene-kanamycin B
3',4'-Episulfido-penta-N-~-butoxycarbonyl-4",6"-
0-cyclohexylidene-kanamycin B (585 mg) which was prepared
as in Example 2 (3) was dissolved in methanol (7 ml), to
which was added Raney nickel (R-100)(500 mg) and the
mixture was stirred at room temperature (20C) for 2
hours. After the Raney nickel was removed by filtration,
the filtrate was concentrated to dryness~ affording the
titled compound. Yield 450 mg (80%).
(2) Preparation of 3',4'-dideoxykanamycin B
3',4'-Dideoxy-3'-eno-penta-N-t-butoxy-4",6"-
0-cyclohexylidene-kanamycin B (450 mg) was treated as
.:
- 39

~76;~
similar as in Example 1 (6) and (7), affording the titled
compound. Yield gO%.
Example 6
. .
(1) Preparation of 3',4'-~-epoxy-penta-N-t-butoxycarbonyl-
4"~6"-0-cyclohexylidene-2"-0-benzoyl-kanamycin B
3',4'-~-Epoxy-penta-N t-butoxycarbonyl-4",6"-0-
; cyclohexylidene-kanamycin B (2.0 g) was dissolved in
dry pyridine (40 ml), to which was added benzoyl chloride
(0.8 ml) under ice-cooling and the mixture was allowed to
stand for reaction at 5C for 30 minutes. Then, water
(2 ml) was added to the reaction mixture and the mixture
was concentrated to give a syrup which was then poured
into water (20 ml) to form precipitate. The precipitate
was recovered by filtration and dried to yield the titled
: compound. Yield 2.16 g (98.3%).
(2) ~Preparation of 4'-deoxy-4'-iodo-penta-N-t-butoxy-
carbonyl-4",6"-0-cyclohexylidene-2't-0-benzoyl-kanamycin B~
' 3',4'-~-epoxy-penta-N-t-butoxycarbonyl-4",6"-0-
cyclohexylidene-2"-0-benzoyl-kanamycin B (2.1 g) was
;~ 20 dissolved in acetone (60 ml), to which were added sodium
iodide (1.4 g), sodium acetate (80 mg) and glacial acetic
, . . .
acid (1.4 ml)~and the resulting mixture was refluxed
for about 8 hours.
After the completion of the reaction, the mixture
was cooled to deposlt crystals which were recovered by
filtration. Yield 2.25 g (94%). mp. 171~176C (with
decomposition).
Elementary analysis:
Found. C 52.81; H 7.11; N 5.31; I 10.39%
Calculated for C4 3 H7 6 NsOlgI:
: - . . ' .
', - 1~ o

~7~si6~ .
C 52.62; H 6.94; N 5.48; I 9.93%
t3) Preparation of 3',4'-dideoxy-3'-eno-penta-N-t-buto~y-
carbonyl-4",6"-O-cyclohexylidene-2"-O-benzoyl-kanamycin B
~; 4'-Deoxy-4'-iodo-penta-N-t-butoxy~arbonyl-4",6"-
O-cyclohexylidene-2'l-O-benzoyl-kanamycin B (452 mg~ was
dissolved in dry pyridine (9 ml), to which was added
benzylsulfonyl chloride (305 mg) under cooling to 0~5C
for about 30 minutes.
- After the completion of the reaction, methanol
(0.18 ml) was added to the reaction mixture which was
then heated to 90C for 50 minutes, cooled to room~tem-
`~ perature. The mixture was concentrated to a syrup, to
which water (10 ml) was added to deposit crystals. The
crystals were recovered by filtration and washed with
water to obtain the titled compound in the form of
a wet cake.
Identification of the compound thus obtained
was made by silica-gel thin layer chromatography using
carbon tetrachloride-acetone (4:1 by volume) as developer.
? ~(4) Preparation of 3',4'-dideoxy-3'-eno-penta-N-t-
butoxycar~onyl-4t'~6"-0-cyclohexylidene-kanamycin B
The wet cake of the compound obtained ln the~
step (3) above was~dlssolved~in methanol (20 ml), to
which sodium methylate was added to adjust the pH to
9.0~10.0 and the mixture was~stirred at room temperature
for 30 minutes, neutralized with lN HCl and concentrated
to a syrup. Addition of water to the syrup formed a
precipitate which was recovered by filtration, washed
with water and dried to afford the titled compound.
Yield 360 mg (I00%).
~1 :
:, , , , .:
.:
- : . ... . .

Representative Drawing

Sorry, the representative drawing for patent document number 1076565 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 1997-04-29
Grant by Issuance 1980-04-29

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI
Past Owners on Record
HAMAO UMEZAWA
SHIGEO SEKI
SHUNTARO YASUDA
SHUNZO FUKATSU
SUMIO UMEZAWA
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 1994-04-14 1 28
Cover Page 1994-04-14 1 30
Claims 1994-04-14 3 80
Drawings 1994-04-14 1 13
Descriptions 1994-04-14 40 1,188